Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von JPMorgan Chase & Co. 

AnaptysBio Inc diskutieren

AnaptysBio Inc

WKN: A2AJ8C / Symbol: ANAB / Name: AnaptysBio / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

23,40 €
0,86 %

Einschätzung Sell
Rendite (%) 1,02 %
Kursziel 28,05
Veränderung
Endet am 13.04.24

AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at JPMorgan Chase & Co. from $32.00 to $31.00. They now have an "underweight" rating on the stock.
Ratings data for ANAB provided by MarketBeat

AnaptysBio, Inc. (NASDAQ: ANAB) is now covered by analysts at TD Cowen. They set an "outperform" rating on the stock.
Ratings data for ANAB provided by MarketBeat

AnaptysBio, Inc. (NASDAQ: ANAB) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for ANAB provided by MarketBeat

Einschätzung Buy
Rendite (%) 9,09 %
Kursziel 74,42
Veränderung
Endet am 16.02.25

AnaptysBio, Inc. (NASDAQ: ANAB) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $80.00 price target on the stock.
Ratings data for ANAB provided by MarketBeat

Einschätzung Buy
Rendite (%) 0,00 %
Kursziel 46,24
Veränderung
Endet am 21.02.25

AnaptysBio, Inc. (NASDAQ: ANAB) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $50.00 price target on the stock.
Ratings data for ANAB provided by MarketBeat

Einschätzung Buy
Rendite (%) -3,23 %
Kursziel 50,64
Veränderung
Endet am 26.02.25

AnaptysBio, Inc. (NASDAQ: ANAB) is now covered by analysts at BTIG Research. They set a "buy" rating and a $55.00 price target on the stock.
Ratings data for ANAB provided by MarketBeat

Einschätzung Buy
Rendite (%) 0,84 %
Kursziel 31,15
Veränderung
Endet am 12.03.25

AnaptysBio, Inc. (NASDAQ: ANAB) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. They now have a $34.00 price target on the stock, up previously from $20.00.
Ratings data for ANAB provided by MarketBeat

Einschätzung Buy
Rendite (%) 17,59 %
Kursziel 44,18
Veränderung
Endet am 16.04.25

AnaptysBio, Inc. (NASDAQ: ANAB) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $47.00 price target on the stock.
Ratings data for ANAB provided by MarketBeat

Einschätzung Buy
Rendite (%) 8,33 %
Kursziel 31,56
Veränderung
Endet am 10.05.25

AnaptysBio, Inc. (NASDAQ: ANAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $34.00 price target on the stock.
Ratings data for ANAB provided by MarketBeat